Advertisement
U.S. markets closed

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - Nasdaq Real Time Price. Currency in USD
0.2710-0.0189 (-6.52%)
At close: 04:00PM EDT
0.2727 +0.00 (+0.63%)
After hours: 06:08PM EDT
Full screen
Loading interactive chart...
  • Thomson Reuters StreetEvents

    Q4 2023 Matinas BioPharma Holdings Inc Earnings Call

    Q4 2023 Matinas BioPharma Holdings Inc Earnings Call

  • GlobeNewswire

    Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

    Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improve

  • GlobeNewswire

    Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

    Matinas' Positivein vivo Safety Data with its Oral LNC-Docetaxel Formulation Oral LNC-Docetaxel is significantly less toxic than IV-Docetaxel Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-docetaxel Management to host to 2023 Fina